See the DrugPatentWatch profile for Spiriva
Spiriva Respimat 1.25 mcg is a medication used to manage certain respiratory conditions. The "1.25 mcg" refers to the dosage strength of the active ingredient, tiotropium bromide, delivered per actuation.
What conditions does Spiriva Respimat 1.25 mcg treat?
Spiriva Respimat 1.25 mcg is indicated for the long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema [1]. It is also used as a long-term, once-daily treatment to relieve symptoms in patients with asthma [2].
How does Spiriva Respimat 1.25 mcg work?
Spiriva Respimat 1.25 mcg contains tiotropium bromide, which is an anticholinergic bronchodilator. It works by blocking the action of acetylcholine, a substance that causes muscles in the airways to tighten. By blocking acetylcholine, tiotropium bromide relaxes the muscles around the airways, making it easier to breathe [1][2].
How is Spiriva Respimat 1.25 mcg administered?
Spiriva Respimat 1.25 mcg is delivered via an inhaler device called Respimat. Patients inhale the medication once daily. It is important to use the Respimat inhaler as instructed by a healthcare professional to ensure the correct dosage is delivered [1][2].
When does the patent for Spiriva Respimat expire?
The patent landscape for branded medications can be complex, involving multiple patents covering different aspects of the drug and its delivery system. Information regarding the specific expiration dates of patents related to Spiriva Respimat can be found on resources like DrugPatentWatch.com [3].
Are there generic versions of Spiriva Respimat available?
The availability of generic versions of Spiriva Respimat depends on patent expirations and regulatory approvals. Once patents expire and regulatory pathways are cleared, generic manufacturers can seek approval to market their versions of the drug. Patients and healthcare providers can check with regulatory agencies or pharmaceutical databases for the most current information on generic availability.
What are the potential side effects of Spiriva Respimat 1.25 mcg?
Common side effects of Spiriva Respimat 1.25 mcg can include dry mouth, upper respiratory tract infection, cough, and throat irritation. More serious but less common side effects may include urinary retention, glaucoma, or allergic reactions [1][2]. Patients should discuss any concerns about side effects with their doctor.
How does Spiriva Respimat compare to other COPD or asthma treatments?
Spiriva Respimat is a long-acting bronchodilator that is typically used as a maintenance therapy for COPD and asthma. Its effectiveness and side effect profile are considered in comparison to other classes of respiratory medications, such as short-acting bronchodilators, long-acting beta-agonists (LABAs), inhaled corticosteroids (ICS), and combination therapies. The choice of treatment depends on the individual patient's condition, symptom severity, and response to therapy [1][2].
Where can I find more information about Spiriva Respimat patents?
DrugPatentWatch.com provides detailed information on drug patents, including those related to Spiriva Respimat. This resource can help track patent status and potential dates for market exclusivity expiration [3].
What is the typical cost of Spiriva Respimat 1.25 mcg?
The cost of Spiriva Respimat 1.25 mcg can vary significantly based on factors such as insurance coverage, pharmacy, and geographic location. Patients may be eligible for patient assistance programs offered by the manufacturer or through other healthcare organizations.
What should I do if I miss a dose of Spiriva Respimat 1.25 mcg?
If a dose of Spiriva Respimat 1.25 mcg is missed, it should be taken as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the patient should resume their regular dosing schedule. It is important not to double the dose. Patients should consult their healthcare provider for specific guidance [1][2].
Sources:
[1] https://www.drugs.com/spiriva.html
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022051s017,022124s012lbl.pdf
[3] https://drugpatentwatch.com/